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Introduction: Our previous study showed that pretreatment serum
or plasma Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry may predict clinical outcome of non-
small cell lung cancer (NSCLC) patients treated with epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In
this study, plasma proteomic profiles of NSCLC patients were
evaluated in the course of EGFR TKIs therapy.
Materials and Methods: Plasma samples were collected at base-
line, in the course of gefitinib therapy and at treatment withdrawal.
Samples were analyzed by Matrix-Assisted Laser Desorption/Ion-
ization Time-of-Flight Mass Spectrometry. Acquired spectra were
classified by the VeriStrat test into “good” and “poor” profiles. The
association between VeriStrat classification and progression-free
survival (PFS) and overall survival (OS), and types of clinical
progression, was analyzed.
Results: Plasma samples from 111 NSCLC patients treated with
gefitinib were processed. VeriStrat “good” classification at baseline
correlated with longer PFS (hazard ratio [HR], 0.54; 95% confidence
interval, 0.35–0.83; p  0.005) and OS (HR, 0.40; 95% confidence
interval, 0.26–0.61; p  0.0001), when compared with VeriStrat
“poor.” Multivariate analysis confirmed longer PFS (HR, 0.52; p 
0.025) and OS (HR, 0.44; p  0.001) in patients classified as
VeriStrat “good”, when VeriStrat was considered as a time-depen-
dent variable. About one-third of baseline “good” classifications had
changed to “poor” at the time of treatment withdrawal; progression
in these patients was associated with the development of new
lesions.
Conclusions: Our findings support the role of VeriStrat in the
assistance in treatment selection of NSCLC patients for EGFR TKI
therapy and its potential utility in treatment monitoring.
Key Words: Non-small cell lung cancer, Epidermal growth factor
receptor tyrosine kinase inhibitors, Proteomics, Resistance to epi-
dermal growth factor tyrosine kinase inhibitor.
(J Thorac Oncol. 2012;7: 40–48)
The epidermal growth factor receptor (EGFR) pathwayplays a key role in the development and progression of
non-small cell lung cancer (NSCLC) and many other malig-
nant epithelial tumors.1 Major achievements in the treatment
of lung, colorectal, and head and neck cancer were associated
with the development of targeted drugs inhibiting the EGFR
pathway.2
Gefitinib and erlotinib are oral EGFR tyrosine kinase
inhibitors (EGFR TKIs) shown to be active in NSCLC
patients.3–7 Nevertheless, despite a high expression level of
EGFR receptor in most lung cancers, only a certain fraction
of NSCLC patients benefits from EGFR TKIs.8 Identification
of biomarkers predictive of response to treatment became a
focus of the clinical research in the recent decade. Multiple
studies have shown a positive correlation between activating
EGFR gene mutations (exon 19 deletion, exon 18 G719X,
and exon 21 L858R mutations), response rate, and progres-
sion-free survival (PFS) for EGFR-TKI therapies.9–14 Results
from recent phase III clinical trials, comparing gefitinib and
chemotherapy arms in front line (IPASS, First SIGNAL, NEJ002,
andWJTOG 3405)15–18 and in second line (INTEREST),19,20 have
led to the regulatory approval of gefitinib in Europe in all
lines of therapy for patients carrying EGFR mutations. At the
same time, the INTEREST study showed that in unselected
and EGFR wild-type patients, gefitinib and docetaxel provide
similar PFS and overall survival (OS).19,20 The BR.21 trial7
(phase III trial of erlotinib versus placebo in previously
treated advanced NSCLC patients) showed that erlotinib
significantly prolonged OS, compared with placebo, leading
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to acceptance of erlotinib as a treatment in advanced NSCLC
patients after the failure of first line chemotherapy. Never-
theless, correlative studies performed in a subset of patients
with available tissue enrolled in the BR.21 trial showed that
EGFR mutations were prognostic for OS but were not pre-
dictive, whereas increased EGFR copy number was both
prognostic and predictive for OS benefit.21 None of measured
biomarkers was predictive of OS in the INTEREST trial.20
Considering that prolonged OS and stabilization of the
disease are important criteria of benefit from treatment, es-
pecially in advanced lines of treatment, and taking into
account the low frequency of EGFR mutations in the Cauca-
sian population (approximately 10%),22 and possible discor-
dance in the mutation status between primary NSCLC and
corresponding metastatic tumors,23,24 and absence of consen-
sus on the role of molecular markers in second-line treatment
selection in EGFR wild-type patients, it is of clinical impor-
tance to find additional independent biomarkers predictive of
benefit from treatment. The insufficient availability of tumor
tissue for molecular analysis, which ranges between 20 and
30% even in large well-designed clinical trials, makes the
discovery and validation of a serum or plasma-based predic-
tive test especially desirable. In addition, such a noninvasive
test, if it were correlated with a switch from drug sensitivity
to drug resistance, would be extremely valuable in monitor-
ing the onset of the acquired resistance that eventually de-
velops in the majority of patients, even those with good initial
clinical response.25
In our previous multiinstitutional study, Matrix-Assisted
Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
(MALDI ToF MS) was used to build, develop, and indepen-
dently validate a serum/plasma test (VeriStrat), able to identify,
before treatment, a subset of NSCLC patients with better
outcome from EGFR TKI therapy in terms of time to pro-
gression and OS.26 The algorithm in the core of the test uses
the integrated intensities of eight mass spectral peaks and
assigns a classification label “good” or “poor” or “indetermi-
nate.” The identity of the peaks constituting the test and the
underlying biological mechanism related to the VeriStrat
signature are subjects of ongoing investigations. The test was
developed using a training set of samples from three different
cohorts of patients treated with gefitinib and validated in
blinded fashion in two other independent cohorts treated with
gefitinib and erlotinib and in three control cohorts of patients
treated with chemotherapy and surgery. The blinded valida-
tion showed statistically significant separation in terms of
both OS and in terms of time to progression in NSCLC
patients treated with EGFR TKIs, whereas no statistically
significant separation was observed in cohorts treated with
chemotherapy or surgery. The original study was followed by
multiple clinical validation studies in NSCLC and in other
epithelial tumors. Application of VeriStrat to a subset of
samples from the BR.21 trial showed that the test has a
significant prognostic component, i.e., demonstrates a sepa-
ration by VeriStrat for OS and PFS both in placebo and in
treatment arms. However, VeriStrat “good” patients received
statistically significant benefit from erlotinib therapy over
placebo, whereas in VeriStrat “poor” patients, the separation
was not statistically significant. In addition, VeriStrat classi-
fication was predictive of objective response to erlotinib and
significantly correlated with disease control rate in the treat-
ment arm.27 VeriStrat predicted OS of patients with head and
neck squamous cell carcinoma (HNSCC) treated with ge-
fitinib, erlotinib/bevacizumab, and cetuximab and PFS in
colorectal cancer patients treated with cetuximab; a chemo-
therapy cohort again showed no statistically significant sur-
vival difference.28 In the case of combination therapy target-
ing EGFR and vascular endothelial growth factor (VEGF),
the magnitude of separation, in comparison with monothera-
pies, increased dramatically.29 The body of results obtained
demonstrated the applicability of VeriStrat in various types of
epithelial cancers and in a variety of targeted therapies,
including EGFR-TKIs, anti-EGFR, and anti-VEGF antibod-
ies and their combinations. The dependence of the magnitude
of the separation of survival curves between VeriStrat “good”
and “poor” patients on the particular treatment suggests the
relation of the test not just to the natural history of the disease
of a patient, but to the therapy itself, and provides additional
evidence of VeriStrat predictive properties.
The results obtained in the analyses of pretreatment
samples inspired the current study of the stability of VeriStrat
classification in the course of gefitinib treatment of NSCLC
patients, as well of the possible correlation of its changes with
disease progression, and of the potential utility of the test for
treatment monitoring.
MATERIALS AND METHODS
Patient and Sample Characteristics
This is a retrospective study of samples from NSCLC
patients treated with gefitinib in advanced lines of treatment
at the Scientific Institute San Raffaele University Hospital of
Milan, Italy. Patients provided written informed consent for
the study; analyses were performed under the protocol ap-
proved by the local institutional review boards. Eligibility
criteria included patients aged 18 years and older with cyto-
logical or histological diagnosis of advanced or inoperable
NSCLC; Eastern Cooperative Oncology Group performance
status (ECOG PS) 2; adequate hepatic (total bilirubin
2.5 the upper limit of normal and AST 2.5 normal)
function, treatment with gefitinib at the recommended dose
(250 mg/daily). Plasma samples were collected at baseline,
after 1 month and concomitantly with CT scan evaluation
performed every other month until withdrawal from treatment
with EGFR TKIs for either toxicity or progression. Progres-
sion was defined according to RECIST criteria, version 1.0.
CT scan evaluation was performed by a designated radiolo-
gist. The collected blood was centrifuged at 2000g for 10
minutes at 4°C, and plasma was separated, aliquoted, and
properly stored at 80°C at Scientific Institute San Raffaele
University Hospital of Milan, Italy, until analysis.
MALDI ToF Mass Spectrometry
Proteomic spectra were collected in the Biological
Spectra Unit at the Scientific Institute San Raffaele Univer-
sity Hospital, Milan, Italy. Mass spectra were generated on a
Voyager DE-STR MALDI ToF mass spectrometer (Applied
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Biosystems, Framingham, MA). Plasma was thawed on ice
and diluted 1:10 in deionized water. One microliter of each
diluted sample was spotted on the MALDI target and 1 l of
matrix solution (35 mg/ml sinapinic acid [Sigma, St. Louis,
MO], 50% acetonitrile [Burdick & Jackson, Muskegon, MI],
and 0.1% trifluoroacetic acid [Sigma]) was added. The solu-
tion was mixed by drawing the mixture up and down into the
pipette tip 10 times and then expelling it. The MALDI plates
were then allowed to dry at room temperature in a dark place.
Samples were spotted in triplicate on the MALDI target and
at least three spectra were collected for each sample. Positive
ion mass spectra were acquired in linear mode in an auto-
mated manner. One hundred fifty shots were collected from
four unique locations within the perimeter of each MALDI
spot to generate an average spectrum from 600 independent
spectra for each plasma specimen. Raw spectra were sent
electronically to Biodesix (Steamboat Springs, CO) and an-
alyzed using the previously validated VeriStrat algorithm
(Biodesix, Inc.) that assigns either “good” or “poor” or
“indeterminate” classification to a sample.
EGFR Mutational Status and EGFR Gene
Amplification
All specimens were obtained from the original biopsy,
before any treatment. GenomicDNA was derived from tumor
tissue after laser capture microdissection. Deletions in exon
19 (del 19) were determined by length analysis after poly-
merase chain reaction amplification with the use of a FAM-
labeled primer in an ABI Prism 3130 DNA Analyzer (Ap-
plied Biosystems). Exon 21 point mutations in codon 858
were detected with a 5 nuclease PCR assay (TaqMan assay)
using FAM and VIC MGB-labeled probes for the wild type
and the mutant sequence, respectively. All mutants were
confirmed by DNA sequencing.
Gene copy number per cell was investigated by fluo-
rescence in situ hybridization (FISH) using the LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen probe (Vysis; Ab-
bott Laboratories, IL), according to a published protocol.30
High EGFR gene copy number was defined as high polysomy
(4 copies in40% of cells) or gene amplification (presence
of tight gene clusters; a gene: chromosome ratio per cell of
2; or 15 copies of EGFR per cell in 10% of cells
analyzed).
Statistical Analysis
PFS was defined as the time from the beginning of
gefitinib treatment to first appearance of progressive disease
or death from any cause. Patients known to be alive, and who
had not progressed at the time of analysis were censored at
their last available follow-up assessment. OS was defined as
the time from the beginning of gefitinib treatment to the date
of death from any cause. Patients not reported as having died
at the time of the analysis were censored at the date they were
last known to be alive.
Survival curves were estimated using the Kaplan-Meier
method. Cox proportional hazards models were used for
univariate and multivariate analyses to test demographic
characteristics, clinical features, and VeriStrat profile (in-
cluded as time-dependent variable) for their associations with
PFS and OS. Variables found to be associated (p 0.10) with
PFS and OS in the univariate model were included in the
multivariate analysis. A logistic regression model was used to
assess the association of demographic characteristics and
clinical features with VeriStrat status at baseline. Correlation
between EGFR amplification by FISH and VeriStrat classi-
fication was assessed with 2 test. Results were expressed as
hazard ratios (HRs) or odds ratios (ORs) and relative 95%
confidence intervals (CIs). The statistical significance was set
at p 0.05 for a bilateral test. Analyses were carried out with
SAS Software, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Patients’ Characteristics
Consecutive plasma samples from NSCLC patients,
admitted to Scientific Institute San Raffaele Hospital from
October 2001 until December 2004 and included in the
previous study,26 were collected in the course of treatment
and evaluated in this study. One hundred eleven patients
having received gefitinib for a median duration of 3.5 (range,
0.7–47.0) months were analyzed. Patients’ characteristics are
shown in Table 1. Patients were predominantly males (77%),
ever smokers (84%), with ECOG-PS of 0–1 (82%). The
majority of them (96%) had advanced disease and 50% had
adenocarcinoma histology. Median age was 68 years, ranging
from 36 to 91 years. Most of the patients (72%) were treated
with gefitinib in a second/third-line setting; 21% of patients
received gefitinib as a first-line therapy because of their
clinical conditions and comorbidities.
In the course of treatment and follow-up, 110 patients
progressed and 109 deceased. Median PFS and OS were 3.4
(interquartile range, 2.0–8.5) and 8.3 (interquartile range,
4.0–22.4) months, respectively, as expected in locally ad-
vanced and metastatic NSCLC patients (Supplementary dig-
ital content 1, http://links.lww.com/JTO/A166).
VeriStrat Classification at Baseline
VeriStrat classification was performed at baseline, after
1 month of gefitinib therapy, and every 2 months concomi-
tantly to CT scan evaluation until withdrawal in a total of 476
plasma samples.
At baseline, 69% of patients were classified as VeriStrat
“good” and 28% as VeriStrat “poor.” Concordantly with
previously published results,26 only 3% of patients had an
“indeterminate” classification; they were excluded from the
statistical analyses. Patients classified as VeriStrat “good”
had longer PFS (HR, 0.54; 95% CI, 0.35–0.83; p  0.005)
and OS (HR, 0.40; 95% CI, 0.26–0.61; p  0.0001) than
VeriStrat “poor” patients (Figures 1 and 2). VeriStrat “good”
classification was associated with adenocarcinoma histology
and ECOG PS both in univariate and multivariate analyses.
For all other variables, no statistically significant correlation
was detected (Table 2).
VeriStrat Classification in the Course of
Treatment
In the course of treatment (before progression or with-
drawal for other reasons), 98 of 111 (88%) patients main-
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tained their baseline VeriStrat classification and only 13
(11%) presented one or more intraindividual changes of label
(from “good” to “poor” or vice versa). VeriStrat classification
of individual patients in the course of gefitinib treatment,
along with PFS and OS, is presented in Figure 3.
At treatment withdrawal, the number of VeriStrat
“good” profile patients decreased from 69 to 51%, whereas
the number of VeriStrat “poor” profile patients increased
from 28 to 43%; 6 patients (6%) were “indeterminate.” The
data are summarized in Table 3. Twenty of 71 (28%) of
“good” classified patients shifted to a “poor” profile at with-
drawal, and in 90% of these cases they either stopped treat-
ment because of the evidence of new lesions or died early.
Within this subgroup, 61% of patients presented new lesions.
Patients who shifted from “good” to “poor” classification had
a higher risk of developing new lesions in comparison with
other patients (OR, 2.9; 95% CI, 1.02–8.37; p  0.049).
Nevertheless, new lesions were also observed in 22% of
patients who remained “good” at progression. Interestingly,
in 12% of the cases that remained good at progression with
new lesions, the brain was the only site of new metastases. Of
32 baseline VeriStrat “poor” classified patients, 27 (84%)
maintained a “poor” profile at treatment withdrawal, 96% of
whom remained steadily “poor”: 7 of them died within 1
month from the beginning of treatment and 20 patients
progressed early during gefitinib therapy. Of the five patients
who changed profile, one (3%) became “indeterminate” and
four (12%) shifted to “good.” Two of these four patients had
a pronounced clinical benefit and remained on treatment for
3 years.
VeriStrat classification, considered as a time-dependent
variable, had a statistically significant effect both on PFS and
OS. “Good” classification was associated with longer PFS
both in univariate (HR, 0.54; 95% CI, 0.35–0.82; p  0.004)
and multivariate (HR, 0.52; 95% CI, 0.30–0.92; p  0.025)
analysis. “Good” VeriStrat classification was associated with
longer OS both in univariate and multivariate analysis (HR,
0.35; 95% CI, 0.23–0.55; p  0.0001 and HR, 0.44; 95% CI,
TABLE 1. Main Patient Characteristics
Characteristic N %
No. of patients 111 —
Age, yr
Median (range) 68 (36–91)
Sex
Male 86 77
Female 25 23
Smoking history
Ever smoke 88 84
Never smoke 17 16
Unknown 6
ECOG-PS
0 45 41
1 45 41
2 19 18
Unknown 2
Histology
Adenocarcinoma 55 50
Squamous carcinoma 26 23
NSCLC 23 21
BAL 7 6
Stage
Ib/IIb/IIIa 5 4
IIIb 14 13
IV 92 83
Line of treatment
I 23 21
II 40 36
III 40 36
IV 7 6
V 1 1
Treatment duration, mo
Median (range) 3.5 (0.7–47)
NSCLC, non-small cell lung cancer.
FIGURE 1. Progression-free sur-
vival (PFS) according to baseline
VeriStrat classification (HR, 0.54;
95% CI, 0.35–0.83; p  0.005).
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0.26–0.72; p  0.001, respectively). Smoking history,
ECOG-PS, platinum-based first line chemotherapy (only in
univariate analysis), and presence of metastases seemed to
significantly affect PFS and OS in both models. Results are
reported in Table 4.
EGFR Gene Amplification and Mutational
Analysis
Of 111 patients, 17 (15%) had an adequate tissue
sample to perform both EGFR gene amplification and
EGFR mutation analysis; for 34 patients (30%), only
EGFR gene amplification was assessable. Mutation analy-
sis identified one EGFR mutation (exon 21 L858R). No
correlation between known EGFR status and baseline
VeriStrat classification was found (Supplementary digital
content 2, http://links.lww.com/JTO/A167).
DISCUSSION
In our previous work, VeriStrat was developed as a test
for patient selection for EGFRTKIs treatment in NSCLC.
Further studies showed that it was also applicable to other
epithelial cancers, such as colorectal and HNSCC, and to
other targeted therapies, including anti-EGFR and anti-
VEGF, actually demonstrating larger effects in cases of
combination treatments. In the studied chemotherapy-treated
cohorts of NSCLC and HNSCC patients, the test did not
show significant separation of survival curves between
FIGURE 2. Overall survival (OS)
according to baseline VeriStrat clas-
sification (HR, 0.40; 95% CI, 0.26–
0.61; p  0.0001).
TABLE 2. Univariate and Multivariate Logistic Regression Models Assessing the Association
Between Demographic and Clinical Characteristics and Veristrat Good Profile
Characteristics
Univariate
OR (95% CI) p
Multivariate
OR (95% CI) p
Sex
Male Reference Not included
Female 2.17 (0.62–7.02) 0.195
Smoking history
Never smoke Reference Not included
Ever smoke 0.32 (0.07–1.53) 0.156
ECOG-PS
0 Reference Reference
1 0.22 (0.07–0.68) 0.259 0.25 (0.08–0.76) 0.015
2 0.06 (0.02–0.23) 0.0001 0.06 (0.01–0.23) 0.0001
Histology
Other Reference Reference
Adenocarcinoma 2.49 (1.05–5.87) 0.038 2.61 (0.99–6.90) 0.050
Platinum-based I line CHT
No Reference Not included
Yes 1.47 (0.62–3.52) 0.384
ECOG-PS, ECOG performance status; CHT, chemotherapy; CI, confidence interval; OR, odds ratio.
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“good” and “poor” subgroups.26,28 Retrospective analysis of
the available samples from the BR.21 trial showed that the
VeriStrat test has a significant prognostic component, i.e., OS
and PFS were significantly different between VeriStrat
“good” and “poor” groups not only in the erlotinib arm but
also in the placebo arm. Nevertheless, VeriStrat “good”
patients received statistically significant benefit from the
targeted therapy when compared with placebo, whereas in the
VeriStrat “poor” group, this difference was not statistically
significant. Response to treatment was also significantly cor-
related with the VeriStrat “good’ classification.27 Apparently,
differences in PFS and OS of VeriStrat “good” and “poor”
patients are caused by the combination of their prognostic
characteristics and differences in their reaction to specific
treatments. The relative impact of both components depends
on the particular treatment and requires further investigation.
The clinical relevance of VeriStrat in the advanced NSCLC
population is defined by its ability to assist in the choice of
the optimal treatment between chemotherapy and targeted
therapy in the second-line setting. This is especially impor-
tant in EGFR wild-type patients and in patients with unknown
EGFR status.
Our preliminary data presented at 13th World Confer-
ence on Lung Cancer give an indication that VeriStrat “poor”
patients have longer OS when treated with chemotherapy,
rather than with gefitinib, suggesting that chemotherapy
might be preferred in this subgroup. In the VeriStrat “good”
group, there was no statistically significant difference in
survival between the chemotherapy- and gefitinib-treated pa-
tients.32 Taken together, these data suggest that VeriStrat
“poor” classified patients have worse clinical outcome than
VeriStrat “good” patients, especially when treated with tar-
geted agents, whereas chemotherapy might improve survival
in this subgroup. This observation needs further validation
and the ongoing prospective phase III trial “Randomized
Proteomic Stratified Phase III Study of Second Line Erlotinib
versus Chemotherapy in Patients with Inoperable Non-Small
Cell Lung Cancer (PROSE)” was designed to provide further
clarification of this question.
The aim of this study was to investigate possible
changes in VeriStrat classification of plasma samples from
NSCLC patients collected in the course of treatment with
gefitinib, concomitantly with CT evaluations. Statistical re-
analysis of baseline samples, now using the mature survival
data, confirmed a significant separation in OS and PFS curves
between VeriStrat “good” and “poor” patients. Seventy per
cent of patients retained their baseline VeriStrat classification
at treatment withdrawal, whereas 30% experienced a change.
The majority of the observed changes were from “good” to
“poor” at progression of the disease. About one-third of
FIGURE 3. VeriStrat classification of individual patients in course of gefitinib therapy along with progression and death.
TABLE 3. Veristrat Profile at Baseline and at Treatment
Withdrawal
Veristrat Profile
Treatment Withdrawal
TotalGood Poor Indeterminate
Baseline
Good 51 (89) 20 (42) 5 (83) 76 (69)
Poor 4 (7) 27 (56) 1 (17) 32 (28)
Indeterminate 2 (4) 1 (2) 0 (0) 3 (3)
Total 57 (51) 48 (43) 6 (6) 111
Values presented as N (%).
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baseline “good” classifications had changed to “poor,” and in
90% of these cases, progression was associated with the
development of new lesions, detected by radiological assess-
ment, or patients died within 1 month from the start of
treatment. The risk of new lesions in patients with the shift in
classification from “good” to “poor” was significantly higher
than in the rest of the population (OR, 2.9; p  0.049).
There were three distinct types of progression in pa-
tients who remained “good” in the course of observation.
Twenty-two per cent of cases had progression with new
lesions. Other patients did not develop new lesions, and
disease progression was defined as an increase of the target
lesion diameter by RECIST criteria. This observation sup-
ports criticism of the clinical impact of RECIST criteria, in
particular, of the relation between critical dimensional in-
crease of target lesions and OS. Finally, in a small group of
stably “good” patients, progression was diagnosed as occur-
rence of new lesions in the brain only. Apparently, this type
of progression is not associated with changes of VeriStrat
molecular profile, probably because of the specific nature of
brain metastases.
The majority of baseline “poor” patients maintained
their classification in the course of treatment and at with-
drawal; four patients had shifted to “good” and, interestingly,
two of them had pronounced clinical benefits and long sur-
vival times. Of note, the change in the VeriStrat classification
was observed in these patients at the time of the second blood
draw (after 1 month of therapy), whereas the timing of the
baseline sample coincided with patient conditions associated
with acute inflammation, i.e., surgery (femoral prosthesis) in
one case and pulmonary thrombosis in the other case.
In summary, the data obtained in this study indicate that
the molecular species responsible for the VeriStrat mass
spectral signature are time-dependent dynamic markers,
probably related to some specific unknown primary (in the
case of baseline VeriStrat “poor” patients) or acquired (in the
case of change of classification from “good” to “poor”)
EGFR TKI resistance mechanisms. Recent results presented
at 2011 AACR conference showed that VeriStrat “poor” and
“good” serum can have different biological effects on
NSCLC cell lines: incubation of HCC4006 EGFR-TKI sen-
sitive cell lines in a medium containing 10% serum from
VeriStrat “poor” patients increased the resistance of these
cells to gefitinib, whereas addition of VeriStrat “good” serum
did not cause changes in the drug sensitivity. These data
support the hypothesis that the VeriStrat “poor” signature
may be associated with some mechanisms that influence cell
sensitivity to targeted agents.33 The ongoing study aimed at
the identification of the proteins constituting the VeriStrat
mass-spectral signature and understanding the biological
mechanism associated with it is supported by Associazione
Italiana sulla Ricerca del Cancro.
TABLE 4. Results of Cox Univariate and Multivariate Analyses for Progression-Free Survival (PFS) and Overall Survival (OS)
Characteristics
PFS Univariate
HR (95% CI) p
Multivariate
HR (95% CI) p
OS Univariate
HR (95% CI) p
Multivariate
HR (95% CI) p
Sex
Male Reference Not included Reference Not included
Female 0.76 (0.49–1.20) 0.237 0.83 (0.53–1.30) 0.410
Smoking history
Never smoke Reference Reference Reference Reference
Ever smoke 1.50 (1.13–1.99) 0.005 2.87 (1.58–5.24) 0.001 1.32 (0.99–1.76) 0.059 1.80 (1.00–3.232) 0.001
ECOG-PS
0 Reference Reference
1 1.06 (0.70–1.60) 0.781 1.30 (0.82–2.06) 0.015 1.24 (0.82–1.89) 0.315 1.44 (0.92–2.24) 0.107
2 1.80 (1.04–3.10) 0.036 2.18 (1.05–4.51) 0.037 2.50 (1.44–4.34) 0.001 2.50 (1.30–4.78) 0.006
Histology
Other Reference Not included Reference Not included
Adenocarcinoma 1.11 (0.92–1.34) 0.275 0.97 (0.80–1.17) 0.719
Platinum-based I
line CHT
No Reference Reference Reference Not included
Yes 1.51 (1.00–2.23) 0.050 1.73 (0.94–3.21) 0.080 1.21 (0.80–1.82) 0.360
Metastases
No Reference Reference Reference Not included
Yes 1.90 (1.12–3.22) 0.018 2.37 (1.33–4.33) 0.003 1.48 (0.89–2.25) 0.135
Line of treatmenta 1.19 (0.97–1.45) 0.091 0.96 (0.72–1.28) 0.767 0.98 (0.81–1.20) 0.874 Not included
Veristrat profileb
Poor Reference Reference Reference Reference
Good 0.54 (0.35–0.82) 0.004 0.52 (0.30–0.92) 0.025 0.35 (0.23–0.55) 0.0001 0.44 (0.26–0.72) 0.001
a Included as continuous variable.
b Included as time-dependent variable.
PFS, progression-free survival; OS, overall survival; ECOG-PS, ECOG performance status; CHT, chemotherapy; HR, hazard ratio; CI, confidence interval; OR, odds ratio.
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Although sensitivity to EGFR-TKIs is considered to be
associated with activating mutations in tyrosine-kinase do-
main, the data on primary resistance in NSCLC are conflict-
ing, with some studies showing the involvement of KRAS,
BRAF, and PI3K mutations. A secondary T790M mutation in
the kinase domain of the EGFR34 and activation of alternative
pathways allowing the bypassing of inhibition of EGFR
signaling, such as overexpression of hepatocyte growth fac-
tor35 and MET amplification,36 activation of AKT/mTOR, or
changes in signaling via insulin-like growth factor-1 recep-
tor,37–39 are known resistance mechanism to EGFR TKI
therapy.
Available data on the VeriStrat test in relation to
studied genetic markers obtained in the retrospective analysis
of the BR.21 study27 as well on several smaller studies28,40
did not show any significant correlations between VeriStrat
classification and EGFR mutational status, EGFR gene am-
plification, or KRAS mutations. In this study, we also did not
find a correlation between EGFR gene amplification by FISH
and VeriStrat. Possible associations with other genetic char-
acteristics, especially with T790M, need further investiga-
tion. Nevertheless, it has been shown that the T790M in-
creases ATP affinity only for the EGFR mutant L858R and
not for the wild-type receptor, which is a predominant pop-
ulation in our study.41
In addition, not fully understood mechanisms, probably
involving concomitant activation of multiple, often overlap-
ping signaling pathways, may also be involved in resistance
to targeted agents.42,43 It was shown that lung cancer develops
in a host environment in which the deregulated inflammatory
response promotes tumor progression, and inflammatory me-
diators are derived from neoplastic cells and from stromal and
inflammatory cells surrounding the tumor.44
A substantial role of inflammatory processes in the
resistance mechanisms is supported by a growing body of
experimental evidence. For example, it has been shown that
activation of the proinflammatory cytokine IL-6 reduced the
sensitivity to erlotinib in NSCLC cells harboring EGFR
mutations.45 Activation of the NFkB, a major regulator of
immune response, has been recently proposed as another
resistance mechanism to EGFR TKIs. Low IkB expression
(“high-NFkB” activation state) was predictive of worse PFS
and decreased OS in 52 NSCLC patients harboring EGFR
activating mutations and treated with erlotinib.46 Although
the biological mechanism associated with the VeriStrat test
is as yet unknown, the available body of evidence allows
us to hypothesize that they may be related to host-response
processes.
The results of this study, and previously published data,
suggest that proteins involved with the “poor” signature may
be associated both with the intrinsic resistance to anti-EGFR
agents and with the switch to a certain type of acquired
resistance, which is associated with metastases and the for-
mation of new lesions. This noninvasive test may be espe-
cially useful for the selection of second-line therapy in the
absence of available tumor tissue and in patients who do not
harbor EGFR-activating mutations. The ongoing phase III
PROSE study is prospectively validating this approach. Pos-
sibly the test can be used as an additional tool for treatment
monitoring and investigation of mechanisms of primary and
acquired resistance.
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